20年来,多发性硬化症的皮下干扰素-β1a:当代观点
Mark S Freedman1,2, Patricia K Coyle3, Kerstin Hellwig4
1Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada. mfreedman@toh.ca.
Neurology and therapy
|January 11, 2024
概括
用于皮下注射的干扰素β-1a (IFN-β-1a sc) 在治疗复发性复发性多发性硬化症 (RRMS) 中已经证明了20年的有效性和安全性. 它仍然是一个有价值的选择,特别是在特定的患者群体.
科学领域:
- 神经免疫学 神经免疫学
- 临床神经学 临床神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 是一种慢性,渐进的中枢神经系统炎症性疾病.
- 复发性复发性多发性硬化 (RRMS) 是最常见的形式,标志着神经功能障碍和累积残疾.
- 在过去的三十年中,疾病修饰疗法 (DMT) 已被开发用于管理RRMS.
研究的目的:
- 在RRMS治疗中,审查20年的临床数据和使用干扰素β-1a用于皮下注射 (IFN-β-1a sc) 的经验.
- 突出IFN-β-1a sc在特定临床场景中的持续相关性.
- 为了强调其作为研究比较者的作用.
主要方法:
- 对IFN-β-1a sc.的关键试验,现实数据和长期延伸研究 (长达15年) 的审查.
- 对支持有效性和安全性的临床数据的分析.
- 检查其在当前临床实践和研究中的使用情况.
主要成果:
- 1990年代末-2000年代初批准的IFN-β-1a sc在RRMS治疗方面拥有20年的强大记录.
- 广泛的数据证实了它的疗效和安全性.
- 它仍然是一个可行的治疗选择,特别是对于计划怀孕,哺乳期和老年患者.
结论:
- IFN-β-1a sc是RRMS的成熟的DMT,具有长期安全性和有效性记录.
- 它的实用性扩展到特定的患者群体,其中长期免疫抑制是一个问题.
- 该药物作为MS研究和临床试验的关键基准.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...